Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: A case series [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 1, 2005, Pages 126-128

  Antoniou, Tony ^a   Yoong, Deborah ^a   Beique, Lizanne ^b   Chihrin, Steve ^c   Rachlis, Anita ^e   Gough, Kevin ^a,e   Loutfy, Mona R ^c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MAPLE LEAF MEDICAL CLINIC   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTACID AGENT; ATAZANAVIR; CALCIUM CARBONATE; DIDANOSINE; EFAVIRENZ; ESOMEPRAZOLE; LAMIVUDINE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH PH; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTACIDS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES;

EID: 18144409811     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000160518.12957.c0     Document Type: Letter

References (8)

1. Orrick JJ, Steinhart CR. Atazanavir. AnnPharmacother. 2004;38:1664-1674.
2. Bristol-Myers Squibb. Atazanavir (Reyataz) product information. Princeton, NJ: Bristol-Myers Squibb; 2004.
3. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract 504]. Presented at: Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco.
4. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000;44:2093-2099.
5. Colonno RJ, Thiry A, Limoli K, et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47:1324-1333.
6. Yerly S, Vora S, Gunthard H, et al. Virological response following switch to atazanavir/ritonavir in relation to baseline genotypic resistance pattern. Antivir Ther. 2004;9(Suppl):S165.
7. Farthing C, Kanlou H. Co-administration of atazanavir with proton-pump inhibitors and h2-blockers [abstract P289]. Presented at: Seventh International Congress on Drug Therapy in HIV Infection; 2004; Glasgow.
8. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159:649-657.